These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37408759)

  • 1. Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.
    Guo Y; Jia J; Hao Z; Yang J
    Front Pharmacol; 2023; 14():1172969. PubMed ID: 37408759
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.
    Messori A; Rivano M; Chiumente M; Mengato D
    Chin Clin Oncol; 2023 Oct; 12(5):50. PubMed ID: 37817505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
    Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
    Liang H; Lin G; Wang W; Huang J; Yang Y; Lan Y; Wang R; Cui F; Hao Z; Deng H; Zhao S; Cheng B; Xiong S; Li J; Li C; Liu J; He J; Liang W
    Transl Lung Cancer Res; 2020 Apr; 9(2):188-203. PubMed ID: 32420059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
    Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
    BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis.
    Zhang X; Wu M; Chen J; Zheng K; Du H; Li B; Gu Y; Jiang J
    Heliyon; 2024 May; 10(10):e30809. PubMed ID: 38774326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Kim R; Keam B; Hahn S; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
    Clin Lung Cancer; 2019 Sep; 20(5):331-338.e4. PubMed ID: 31164319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
    Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
    Sun H; Bu F; Li L; Zhang X; Xin X; Yan J; Huang T
    Ann Pharmacother; 2024 Apr; 58(4):349-359. PubMed ID: 37488978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
    Zhou Y; Zhang Y; Guo G; Cai X; Yu H; Cai Y; Zhang B; Hong S; Zhang L
    Clin Transl Med; 2020 Jan; 10(1):107-115. PubMed ID: 32508007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Wang L; Yang Y; Yu J; Zhang S; Li X; Wu X; Nie X; Liu W; Zhang P; Li Y; Li A; Ai B
    Thorac Cancer; 2022 Feb; 13(3):322-337. PubMed ID: 34907661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.
    Liu W; Huo G; Chen P
    BMC Cancer; 2023 May; 23(1):458. PubMed ID: 37202730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.